首页> 外国专利> METHOD FOR TREATING DYSFUNCTIONAL UTERINE HEMORRHAGES AT GLANDULAR-CYSTIC HYPERPLASIA AND ENDOMETRIAL POLYPS

METHOD FOR TREATING DYSFUNCTIONAL UTERINE HEMORRHAGES AT GLANDULAR-CYSTIC HYPERPLASIA AND ENDOMETRIAL POLYPS

机译:治疗腺囊性增生和子宫内膜息肉的功能障碍性子宫出血的方法

摘要

FIELD: medicine, gynecology, endocrinology.;SUBSTANCE: it is necessary to detect the level of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) during the period of preovulatory peak, the FSH/LH ratio, the quantity of dominant follicles. During the next menstrual cycle on the day of the onset of LH level growth one should perorally introduce 2000 mcg potassium iodide (PI) in case of one follicle under maturation and 3000 mcg PI at two and more follicles under maturation. During the period of preovulatory FSH and LH peak one should detect their level and ratio, and on the day of maximal secretory activity of endometrial glands it is important to estimated the thickness of endometrium. At decreased FSH/LH ratio and decreased endometrial thickness up to the norm it is necessary to prescribe the repeated intake of the above-mentioned dosage of the preparation but in 3 mo, not earlier and in 6 mo, not later. In case of normal FSH/LH and endometrial thickness the maintenance dosage (MD) corresponds to 1000 mcg PI on the day of the onset of LH level growth at frequency being once/3 mo. In case of increased FSH/LH MD corresponds to 1000 mcg PI at frequency of once/2 mo. In case of amenorrhea without climacteric FSH and LH values MD corresponds to 1000 PI on the day that correspond to previously detected onset of LH level growth, at frequency being once/3 mo till achieving climacteric FSH and LH values. The innovation provides efficient therapy and prophylaxis of dysfunctional uterine hemorrhages at no side effects and no usage of hormonal preparations.;EFFECT: higher efficiency of therapy.;3 cl, 3 ex
机译:领域:医学,妇科,内分泌科;物质:有必要在排卵高峰期检测促卵泡激素(FSH)和黄体生成激素(LH)的水平,FSH / LH比,优势卵泡的数量。在LH水平开始发作的下一个月经周期中,如果一个卵泡处于成熟状态,则应该口服2000 mcg碘化钾(PI),如果两个卵泡处于成熟状态,则应口服3000 mcg PI。在排卵前FSH和LH高峰期,应检测其水平和比率,在子宫内膜腺分泌最大的活动当天,估计子宫内膜厚度很重要。在FSH / LH比降低和子宫内膜厚度降低到正常水平的情况下,有必要规定重复服用上述剂量的制剂,但要在3个月(不早于6mo,不晚于3mo)中重复服用。在正常FSH / LH和子宫内膜厚度的情况下,维持剂量(MD)对应于LH水平开始发作之日1000 mcg PI,频率为一次/ 3 mo。如果FSH / LH增加,则MD对应于1000 mcg PI,频率为一次/ 2 mo。在没有更年期FSH和LH值的闭经的情况下,MD相当于当天的1000 PI,对应于先前检测到的LH水平增长的发作,频率为一次/ 3个月一次,直到达到更年期FSH和LH值。该创新提供了有效的治疗方法,可预防功能失调性子宫出血,且无副作用,无需使用激素制剂。;效果:更高的治疗效率; 3 cl,3 ex

著录项

  • 公开/公告号RU2310459C1

    专利类型

  • 公开/公告日2007-11-20

    原文格式PDF

  • 申请/专利权人 BASALAEVA NADEZHDA LVOVNA;

    申请/专利号RU20060103156

  • 发明设计人 BASALAEVA NADEZHDA LVOVNA;

    申请日2006-02-03

  • 分类号A61K33/18;A61P15/00;

  • 国家 RU

  • 入库时间 2022-08-21 19:50:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号